• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Philip Morris International Inc

    4/28/25 8:33:44 PM ET
    $PM
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $PM alert in real time by email
    FWP 1 tm2513069d3_fwp.htm FWP

     

    Filed Pursuant to Rule 433

    Registration No. 333-269690

     

    FINAL TERM SHEET

     

    Philip Morris International Inc.

     

    Dated April 28, 2025

     

    Floating Rate Notes due 2028

    4.125% Notes due 2028

    4.375% Notes due 2030

    4.875% Notes due 2035

     

    Issuer: Philip Morris International Inc.
    Offering Format: SEC Registered
    Security:

    Floating Rate Notes due 2028 (the “Floating Rate Notes”)

    4.125% Notes due 2028 (the “2028 Notes”)

    4.375% Notes due 2030 (the “2030 Notes”)

    4.875% Notes due 2035 (the “2035 Notes”)

    Aggregate Principal Amount:

    Floating Rate Notes: $400,000,000

    2028 Notes: $750,000,000

    2030 Notes: $750,000,000

    2035 Notes: $600,000,000

    Maturity Date:

    Floating Rate Notes: April 28, 2028

    2028 Notes: April 28, 2028

    2030 Notes: April 30, 2030

    2035 Notes: April 30, 2035

    Coupon:

    Floating Rate Notes: Compounded SOFR (calculated as described in that certain preliminary prospectus supplement of the Issuer dated April 28, 2025), plus 0.83% per annum

    2028 Notes: 4.125%

    2030 Notes: 4.375%

    2035 Notes: 4.875%

     

     

     

     

    Interest Payment Dates:

    Floating Rate Notes: Quarterly on each January 28, April 28, July 28 and October 28, commencing July 28, 2025

    2028 Notes: Semi-annually on each April 28 and October 28, commencing October 28, 2025

    2030 Notes: Semi-annually on each April 30 and October 30, commencing October 30, 2025

    2035 Notes: Semi-annually on each April 30 and October 30, commencing October 30, 2025

    Record Dates:

    Floating Rate Notes: January 13, April 13, July 13 and October 13

    2028 Notes: April 13 and October 13

    2030 Notes: April 15 and October 15

    2035 Notes: April 15 and October 15

    Price to Public:

    Floating Rate Notes: 100.00% of principal amount

    2028 Notes: 99.658% of principal amount

    2030 Notes: 99.190% of principal amount

    2035 Notes: 97.994% of principal amount

    Underwriting Discount:

    Floating Rate Notes: 0.200% of principal amount

    2028 Notes: 0.200% of principal amount

    2030 Notes: 0.300% of principal amount

    2035 Notes: 0.450% of principal amount

    Net Proceeds:

    Floating Rate Notes: $399,200,000 (before expenses)

    2028 Notes: $745,935,000 (before expenses)

    2030 Notes: $741,675,000 (before expenses)

    2035 Notes: $585,264,000 (before expenses)

    Benchmark Treasury:

    Floating Rate Notes: N/A

    2028 Notes: 3.750% due April 15, 2028

    2030 Notes: 3.875% due April 30, 2030

    2035 Notes: 4.625% due February 15, 2035

     

     

     

     

    Benchmark Treasury Price/Yield:

    Floating Rate Notes: N/A

    2028 Notes: 100-07 ¼ / 3.668%

    2030 Notes: 100-09 ¾ / 3.808%

    2035 Notes: 103-11 / 4.204%

    Spread to Benchmark Treasury:

    Floating Rate Notes: N/A

    2028 Notes: +58 basis points

    2030 Notes: +75 basis points

    2035 Notes: +93 basis points

    Yield to Maturity:

    Floating Rate Notes: N/A

    2028 Notes: 4.248%

    2030 Notes: 4.558%

    2035 Notes: 5.134%

    Optional Redemption:

    Floating Rate Notes:

    Except as noted under the caption “Description of Notes – Redemption for Tax Reasons” in the prospectus supplement, the Floating Rate Notes are not redeemable prior to maturity.

     

    2028 Notes:

    Make-whole redemption at Treasury plus 10 bps

     

    2030 Notes:

    Prior to March 30, 2030: Make-whole redemption at Treasury plus 15 bps

    On or after March 30, 2030: Redemption at par

     

    2035 Notes:

    Prior to January 30, 2035: Make-whole redemption at Treasury plus 15 bps

    On or after January 30, 2035: Redemption at par

    Settlement Date (T+2): April 30, 2025*

     

     

     

     

    CUSIP/ISIN:

    Floating Rate    CUSIP Number: 718172 DS5

    Notes:                   ISIN Number: US718172DS53

     

    2028 Notes:       CUSIP Number: 718172 DR7

                                   ISIN Number: US718172DR70

     

    2030 Notes:       CUSIP Number: 718172 DT3

                                   ISIN Number: US718172DT37

     

    2035 Notes:       CUSIP Number: 718172 DU0

                                   ISIN Number: US718172DU00

    Listing: None
    Joint Book-Running Managers:

    Barclays Capital Inc.

    Mizuho Securities USA LLC

    SMBC Nikko Securities America, Inc.

    Santander US Capital Markets LLC

    Standard Chartered Bank

    Co-Managers:

    DBS Bank Ltd.

    Bank of China (Europe) S.A.

     

     

    Allocations:

      Floating Rate
    Notes
       2028 Notes   2030 Notes   2035 Notes 
    Barclays Capital Inc.  $74,800,000   $140,250,000   $140,250,000   $112,200,000 
    Mizuho Securities USA LLC   74,800,000    140,250,000    140,250,000    112,200,000 
    SMBC Nikko Securities America, Inc.   74,800,000    140,250,000    140,250,000    112,200,000 
    Santander US Capital Markets LLC   74,800,000    140,250,000    140,250,000    112,200,000 
    Standard Chartered Bank   74,800,000    140,250,000    140,250,000    112,200,000 
    DBS Bank Ltd.   13,000,000    24,375,000    24,375,000    19,500,000 
    Bank of China (Europe) S.A.   13,000,000    24,375,000    24,375,000    19,500,000 
    Total  $400,000,000   $750,000,000   $750,000,000   $600,000,000 

     

    * Under Rule 15c6-1 under the Exchange Act, trades in the secondary market are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Notes prior to the delivery date will be required, by virtue of the fact that the Notes initially settle in T+2, to specify an alternate settlement arrangement at the time of any such trade to prevent a failed settlement.

     

    No EEA or UK PRIIPs KID – No EEA or UK PRIIPs key information document (KID) has been prepared as the notes are not available to retail investors in the EEA or the UK.

     

    The issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. toll free at 1-888-603-5847, Mizuho Securities USA LLC toll-free at 1-866-271-7403 or SMBC Nikko Securities America, Inc. toll-free at 1-212-224-5135.

     

     

     

     

     

    Get the next $PM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PM

    DatePrice TargetRatingAnalyst
    5/22/2025$195.00Buy
    Needham
    4/25/2025$170.00Sell → Neutral
    UBS
    3/14/2025Hold → Buy
    Argus
    1/16/2025$140.00Overweight
    Morgan Stanley
    3/5/2024Buy → Hold
    Argus
    2/13/2024Sell → Hold
    Societe Generale
    1/23/2024$105.00 → $86.50Buy → Sell
    UBS
    11/16/2023$95.00Neutral
    Redburn Atlantic
    More analyst ratings

    $PM
    Financials

    Live finance-specific insights

    See more
    • Philip Morris International Reports First-Quarter 2025 Results and Raises 2025 Full-Year Adjusted Diluted EPS Forecast for Currency Only

      Reported Diluted EPS Grew 24.6% to $1.72 Adjusted Diluted EPS Grew 12.7% to $1.69; and by 17.3% excluding currency Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) today announces its 2025 first-quarter results.1 "We achieved exceptionally strong performance in the first quarter, with continued volume growth supporting an excellent top-line performance and very strong margin expansion," said Jacek Olczak, Chief Executive Officer. "Our smoke-free business goes from strength to strength, delivering organic growth of over 20% in net revenues and over 33% in gross profit." "We remain confident in our ability to deliver superior results, despite an uncertain and volatile glob

      4/23/25 6:59:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Court Approves CCAA Plans to Resolve Tobacco Product-Related Claims and Litigation in Canada

      Regulatory News: Philip Morris International Inc. (PMI) has been informed by its deconsolidated Canadian affiliate, Rothmans, Benson & Hedges Inc. (RBH), that the court in RBH's Companies' Creditors Arrangement Act (CCAA) proceeding has approved a plan of compromise and arrangement for RBH (the Plan). The Plan, as approved, will resolve all tobacco product-related claims and litigation in Canada against RBH and its affiliates, including PMI. The court also approved substantially similar plans for Imperial Tobacco Canada Limited and Imperial Tobacco Company Limited (together, ITL) and JTI-Macdonald Corp. (JTIM). As previously disclosed, RBH's court-appointed mediator and monitor filed a pr

      3/7/25 8:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Declares Regular Quarterly Dividend of $1.35 Per Share

      Regulatory News: The Board of Directors of Philip Morris International Inc. (NYSE:PM) today declared a regular quarterly dividend of $1.35 per common share, payable on April 10, 2025, to shareholders of record as of March 20, 2025. The ex-dividend date is March 20, 2025. For more details on stock, dividends and other information, see www.pmi.com/dividend. Philip Morris International: Delivering a Smoke-Free Future Philip Morris International is a leading international tobacco company, actively delivering a smoke-free future and evolving its portfolio for the long term to include products outside of the tobacco and nicotine sector. The company's current product portfolio primarily consist

      3/6/25 10:44:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Temperley Dessislava was granted 1,002 shares, increasing direct ownership by 15% to 7,756 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:43 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Bough Bonin was granted 1,002 shares, increasing direct ownership by 11% to 9,834 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:34 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Harker Victoria D was granted 1,002 shares, increasing direct ownership by 41% to 3,418 units (SEC Form 4)

      4 - Philip Morris International Inc. (0001413329) (Issuer)

      5/9/25 4:54:22 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Philip Morris International Holds 2025 Virtual Annual Meeting of Shareholders

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) held its 2025 Annual Meeting of Shareholders today. André Calantzopoulos, Chairman of the Board, addressed shareholders and answered questions. Jacek Olczak, Chief Executive Officer, gave a business presentation, which included an overview of PMI's: excellent 2024 performance and impressive start to 2025; achievement of several key milestones in its smoke-free journey; positive results in the execution of its multicategory strategy; ability to deliver sustainable growth and returns in 2025 and beyond; steadfast commitment to shareholder returns. "Our smoke-free transformation continues to advance rapidly. We mark

      5/7/25 9:44:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International to Host Webcast of 2025 Virtual Annual Meeting of Shareholders

      Regulatory News: Philip Morris International Inc. (PMI) (NYSE:PM) will host a live audio webcast of its 2025 Annual Meeting of Shareholders on Wednesday, May 7, 2025, at 9:00 a.m. ET. The meeting will be in a virtual format and can be accessed at www.virtualshareholdermeeting.com/PM2025. Presentation slides, script and an archived recording of the webcast will be available at the same link. The recording will be available for one year from the date of the meeting. During the meeting, André Calantzopoulos, Chairman of the Board, and Jacek Olczak, Chief Executive Officer, will address shareholders and answer questions. Only shareholders of record with a valid 16-digit control number will be

      4/30/25 9:00:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International CEO Jacek Olczak Addresses Emerging Global Divide in Regulatory Approaches to Consumer Innovation

      Olczak issues call for pragmatic policies that accelerate advances in public health, noting that approximately 20% of smokers globally lack access to better alternatives to cigarettes Jacek Olczak, Chief Executive Officer of Philip Morris International Inc. (NYSE:PM), outlined the need for common-sense regulations in the consumer goods sector while addressing global leaders at Semafor's annual World Economy Summit in Washington, D.C., on April 25, 2025. Olczak emphasized the sector's potential for innovation-led growth despite the volatile economic environment. He stressed, however, that without appropriate regulation and policy frameworks to enable scientific evaluation and consumer acces

      4/28/25 8:15:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham initiated coverage on Philip Morris International with a new price target

      Needham initiated coverage of Philip Morris International with a rating of Buy and set a new price target of $195.00

      5/22/25 8:27:06 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by UBS with a new price target

      UBS upgraded Philip Morris International from Sell to Neutral and set a new price target of $170.00

      4/25/25 8:25:28 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International upgraded by Argus

      Argus upgraded Philip Morris International from Hold to Buy

      3/14/25 7:44:58 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:21:26 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      2/9/24 6:05:54 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Philip Morris International Inc (Amendment)

      SC 13G/A - Philip Morris International Inc. (0001413329) (Subject)

      1/29/24 3:26:29 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    SEC Filings

    See more
    • SEC Form SD filed by Philip Morris International Inc

      SD - Philip Morris International Inc. (0001413329) (Filer)

      5/15/25 6:05:44 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      5/9/25 11:35:47 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Inc filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Philip Morris International Inc. (0001413329) (Filer)

      5/7/25 9:50:34 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care

    $PM
    Leadership Updates

    Live Leadership Updates

    See more
    • Molex, a Parent to Phillips Medisize, Announces Agreement to Acquire the Vectura Group Limited, Expanding Its Drug Delivery Capabilities in Inhalation

      Pharmaceutical customers and patients to benefit from the combined design, development and manufacturing services of Vectura and Phillips Medisize Phillips Medisize to add a market-leading position in inhalation combination product development to its existing suite of drug delivery device design capabilities Vectura employees to join a large global company, dedicated to improving patients' lives through innovative products and world class quality and manufacturing capabilities Molex, a parent to Phillips Medisize, a leader in the design, engineering and manufacturing of pharmaceutical drug delivery, in vitro diagnostic and medtech devices, announced that, through its affiliate Molex

      9/17/24 9:11:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International Names New External Affairs Leader

      Philip Morris International Inc. (PMI) (NYSE:PM) is pleased to announce the appointment of Christos Harpantidis to the position of Senior Vice President, External Affairs effective May 1, 2024. In his new role, Mr. Harpantidis will report to the company's CEO, Jacek Olczak. "Christos is an experienced business leader with a proven track record of engaging society on the benefits of tobacco harm reduction and risk-proportionate regulation for smoke-free products," said CEO Jacek Olczak. "He has been instrumental in building our smoke-free business in Greece and the South East Europe Area as we evolve away from cigarettes. I'm looking forward to working with Christos and excited to see what

      3/26/24 5:48:00 AM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care
    • Philip Morris International's U.S. Business Champions Female Economic Growth in Connecticut with Record-Setting $5 Million Investment Through New Partnership with Women's Business Development Council

      In honor of Women's History Month and in advance of International Women's Day, investment and partnership support female economic empowerment and equality through entrepreneurship Today, Philip Morris International (PMI) (NYSE:PM) announces the launch of an extended partnership via its U.S. business to support female empowerment with a record-setting $5 million investment in the Women's Business Development Council (WBDC), a 501(c)(3) charitable organization dedicated to providing tools and resources to help women entrepreneurs thrive in business throughout Connecticut. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202403048002

      3/4/24 6:48:00 PM ET
      $PM
      Medicinal Chemicals and Botanical Products
      Health Care